Literature DB >> 18769203

The role of neuromediators in ocular allergy.

Alessandra Micera1, Alessandro Lambiase, Stefano Bonini.   

Abstract

PURPOSE OF REVIEW: To describe and highlight the critical role of neuromediators in ocular allergy, in view of the recent findings indicating that particularly neuropeptides and neurotrophins exert a pivotal role in the complex network of neurogenic inflammation occurring in ocular allergy. RECENT
FINDINGS: Neuropeptides and neurotrophins represent an interesting group of neuromediators actively taking place in allergic response. Mainly released at the neuronal edge or from immune and/or structural cells, neuropeptides and neurotrophins might either upregulate or downregulate inflammatory processes. These mediators contribute to ocular allergy by acting directly on cells responsible for both early and late phase reactions as well as on epithelial cells and fibroblasts, leading to either self-limiting or chronicity states.
SUMMARY: This short review surveys our current knowledge on the functional activity showed by substance P, calcitonin gene-related peptide, vasoactive intestinal peptide, neuropeptide Y and nerve growth factor and integrates their opposing effects in the context of neuroimmune interactions during ocular allergy. In addition, the review will provide implications for the clinical situation and/or future strategies for treating the most severe chronic forms of ocular allergy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18769203     DOI: 10.1097/ACI.0b013e32830e6b17

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  9 in total

Review 1.  TFOS DEWS II pain and sensation report.

Authors:  Carlos Belmonte; Jason J Nichols; Stephanie M Cox; James A Brock; Carolyn G Begley; David A Bereiter; Darlene A Dartt; Anat Galor; Pedram Hamrah; Jason J Ivanusic; Deborah S Jacobs; Nancy A McNamara; Mark I Rosenblatt; Fiona Stapleton; James S Wolffsohn
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

2.  Mechanism of interaction between ocular and nasal neurogenic inflammation in allergic rhinoconjunctivitis.

Authors:  Xiao-Wei Gao; Xiao-Min Zhang; Hai-Yan Liu; Shan-Shan Wang; Hua-Jiang Dong
Journal:  Int Ophthalmol       Date:  2019-01-03       Impact factor: 2.031

3.  Tear levels of neuropeptides increase after specific allergen challenge in allergic conjunctivitis.

Authors:  Marta Sacchetti; Alessandra Micera; Alessandro Lambiase; Stefania Speranza; Flavio Mantelli; Girolamo Petrachi; Sergio Bonini; Stefano Bonini
Journal:  Mol Vis       Date:  2011-01-07       Impact factor: 2.367

4.  The possible link between the elevated serum levels of neurokinin A and anti-ribosomal P protein antibodies in children with autism.

Authors:  Gehan A Mostafa; Laila Y Al-Ayadhi
Journal:  J Neuroinflammation       Date:  2011-12-21       Impact factor: 8.322

5.  Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models.

Authors:  Tadafumi Tamura
Journal:  Asia Pac Allergy       Date:  2012-04-23

Review 6.  Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.

Authors:  Rohan Bir Singh; Lingjia Liu; Ann Yung; Sonia Anchouche; Sharad K Mittal; Tomas Blanco; Thomas H Dohlman; Jia Yin; Reza Dana
Journal:  Ocul Surf       Date:  2021-05-15       Impact factor: 6.268

7.  Nerve growth factor modulates toll-like receptor (TLR) 4 and 9 expression in cultured primary VKC conjunctival epithelial cells.

Authors:  Alessandra Micera; Barbara Stampachiacchiere; Eduardo Maria Normando; Alessandro Lambiase; Sergio Bonini; Stefano Bonini
Journal:  Mol Vis       Date:  2009-10-13       Impact factor: 2.367

8.  Age-Related Cataract Is Associated with Elevated Serum Immunoglobulin E Levels in the South Korean Population: A Cross-Sectional Study.

Authors:  Tae Keun Yoo; Sun Woong Kim; Kyoung Yul Seo
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

9.  A Novel Murine Model of Radiation Keratopathy.

Authors:  Deshea L Harris; Takefumi Yamaguchi; Pedram Hamrah
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-08-01       Impact factor: 4.799

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.